依普利酮的适应症

(eplerenone) is a new type of selective aldosterone receptor antagonist. It was approved for clinical use by the State Food and Drug Administration in 2002. The pure product is white or off-white crystal. It has a stronger antagonistic effect on aldosterone than spironolactone, and has extremely low affinity for androgen and progesterone receptors. It has few adverse reactions. It has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction. It has fewer adverse reactions and good tolerance. It is a good alternative drug to spironolactone.

Eplerenone is used for the treatment of congestive heart failure, hypertension, etc. after acute myocardial infarction.

Eplerenone binds to mineralocorticoid receptors, thereby blocking the binding of aldosterone, a component of the renin-angiotensin-aldosterone system (RAAS). Aldosterone synthesis occurs primarily in the adrenal gland and is regulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium. Aldosterone binds to mineralocorticoid receptors in epithelial tissues (such as the kidneys) and non-epithelial tissues (such as the heart, blood vessels, and brain) and increases blood pressure by inducing sodium reabsorption and possibly other mechanisms.

Common doses for adults with congestive heart failure: Initial dose: 25 mg orally, once daily; gradually increase to target dose within 4 weeks as tolerated by the patient. Target dose: 50 mg orally once daily.

Common dosages for adults with hypertension: (eplerenone) can be used alone or in combination with other antihypertensive drugs. Initial dose: 50 mg orally once daily; Maintenance dose: 50 mg orally once or twice daily; Maximum dose: 100 mg/day. Obvious antihypertensive effects appear within four weeks of taking the drug. Patients whose blood pressure responds inadequately to the initial dose may be increased to 50 mg twice daily.